Despite consistent recommendations and growing clinical evidence, uptake of SGLT2i and GLP1 RA therapies in people with type 2 diabetes and cardiorenal comorbidities has been slow. There is also relatively little research on ethnic differences in those starting second-line therapy. This is an omission, as ethnic minority groups have higher rates of morbidity and mortality associated with type 2 diabetes.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Acute leukemia: Disease management
Priorities from the perspective of patients and family caregivers
- Bronchodilators for asthma
The early bird … gasps for air
- Chronic kidney disease (CKD)
Triage of high-risk patients – Update 2025
- AAD Annual Meeting: Review
HS and acne – what’s new?
- New perspectives for the optimization of cancer immunotherapy
Nanoparticle-mediated intratumoral gene editing of PD-L1 and galectin-9
- Past, present and future
Biomarkers in schizophrenia
- From genome profiles to targeted therapies
Advances in breast cancer therapy in the age of molecular diagnostics
- Current overview of evidence, mechanisms and clinical implications